サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426379

成人悪性神経膠腫治療薬の世界市場レポート 2024

Adult Malignant Glioma Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
成人悪性神経膠腫治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

成人悪性神経膠腫治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.5%の年間複合成長率（CAGR）で32億3,000万米ドルに成長すると予想されます。 成人悪性神経膠腫治療薬の予測期間で予想される成長は、免疫療法、標的療法、バイオマーカーの発見、リキッドバイオプシー技術の応用、およびアクセスプログラムの拡大の進歩に起因すると考えられます。これらの動向は、患者中心の医薬品開発への移行、ファストトラック指定やブレークスルー指定などの規制経路の加速、ドラッグデリバリーシステムの革新、共同調査の取り組み、治療アプローチの強化における人工知能の統合を反映しています。

脳腫瘍症例の増加傾向は、成人悪性神経膠腫治療薬市場の成長を推進する重要な原動力になると予想されます。脳腫瘍は、通常の制御機構を回避した細胞の異常な増殖と無制限の増殖を特徴とする異常な組織塊です。特定の種類の脳腫瘍である成人悪性神経膠腫は、異常で制御されていない増殖パターンを示す細胞で構成されています。成人悪性神経膠腫の治療には、通常、外科的処置、放射線療法、および化学療法の組み合わせが含まれます。この傾向を示すように、米国がん協会の2023年 1月の報告書によると、脳および神経系がんに関連する症例数は2023年に24,810件に増加し、2020年に記録された23,890件から3.85%増加していることが顕著です。腫瘍は成人悪性神経膠腫治療薬市場の拡大の原動力となっています。

脳腫瘍調査に特化した政府資金の注入により、成人悪性神経膠腫治療薬市場の成長軌道は今後大きく推進される予定です。政府の資金提供には、連邦、州、地方などのさまざまなレベルの政府機関が、イニシアチブ、プログラム、プロジェクト、組織、または個人に対して支出する財政支援が伴います。脳腫瘍調査への政府資金の割り当ては、成人悪性神経膠腫治療薬の進歩に大きな期待をもたらします。この資金は、革新的な治療法の開発、ピリミジン合成に焦点を当てたオーダーメイドの医薬品設計、希少疾病用医薬品の承認の迅速化に大きく役立ちます。たとえば、2023年 6月、オーストラリア保健高齢者ケア省はオーストラリア脳腫瘍ミッションを開始し、特に脳腫瘍調査の支援を目的とした1億3,666万米ドルの基金を拠出しました。この取り組みの主な目的は、未分化星状細胞腫を含む脳腫瘍患者の生存率を2倍にし、全体的な生活の質を向上させることです。その結果、脳腫瘍調査に向けた政府の資金提供が、成人悪性神経膠腫治療薬市場を推進する極めて重要な原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の成人悪性神経膠腫治療薬市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 多形膠芽腫
  • 未分化星状細胞腫
  • 未分化希突起膠腫
  • 未分化乏突起星状細胞腫
  • その他のタイプ
  • 世界の成人悪性神経膠腫治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 化学療法
  • 標的療法
  • 放射線療法
  • その他の治療
  • 世界の成人悪性神経膠腫治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • がんおよび放射線治療センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の成人悪性神経膠腫治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の成人悪性神経膠腫治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 成人悪性神経膠腫治療薬市場の競合情勢
  • 成人悪性神経膠腫治療薬市場の企業プロファイル
    • Johnson &Johnson Private Limited
    • Pfizer Inc.
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche Ltd.
    • Allergan plc

第31章 その他の大手および革新的な企業

  • AbbVie Inc.
  • Novartis AG
  • Bayer AG
  • Merck &Co Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Abbott Laboratories
  • AstraZeneca plc
  • Eli Lilly and Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GT Medical Technologies Inc.
  • Lupin Limited
  • Mylan NV
  • Sanofi SA

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13391

The field of adult malignant glioma therapeutics focuses on treating brain tumors that originate in the glial cells of the brain or spinal cord, particularly in adults. This encompasses various treatment options designed to enhance the quality of life and extend the survival of individuals affected by malignant gliomas.

The primary subtypes of adult malignant glioma therapeutics include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM), known for its aggressive nature, involves rapid tumor growth and the infiltration of neighboring brain tissue, typically without distant organ metastasis. Therapeutic interventions in this domain encompass chemotherapy, targeted therapy, radiotherapy, and other modalities. These treatments are administered in various healthcare settings, including hospitals, specialty clinics, and cancer and radiation therapy centers.

The adult malignant glioma therapeutics market research report is one of a series of new reports from The Business Research Company that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.03 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The historical growth in the field of adult malignant glioma therapeutics can be attributed to factors such as an increase in incidence rates, the influence of patient advocacy initiatives, and the adoption of personalized medicine approaches. These factors have contributed to advancements in understanding the disease and tailoring treatment strategies to individual patients, thereby influencing the positive trajectory in this therapeutic domain.

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period for adult malignant glioma therapeutics can be attributed to advancements in immunotherapy, targeted therapies, biomarker discoveries, the application of liquid biopsy techniques, and the expansion of access programs. These trends reflect a shift towards patient-centric drug development, accelerated regulatory pathways such as fast-track and breakthrough designations, innovations in drug delivery systems, collaborative research initiatives, and the integration of artificial intelligence in enhancing treatment approaches.

The upward trajectory in brain tumor cases is anticipated to be a significant driver in propelling the growth of the adult malignant glioma therapeutics market. Brain tumors represent anomalous masses of tissue characterized by the abnormal proliferation and unchecked growth of cells, circumventing the usual regulatory mechanisms. Adult malignant glioma, a specific type of brain tumor, comprises cells exhibiting abnormal and uncontrolled growth patterns. Treatment for adult malignant glioma typically involves a combination of surgical procedures, radiation therapy, and chemotherapy. Illustrating this trend, as per the American Cancer Society's January 2023 report, the number of cases related to brain and nervous system cancers escalated to 24,810 in 2023, demonstrating a notable 3.85% increase from 23,890 recorded in 2020. Thus, the mounting instances of brain tumors serve as a driving force behind the expansion of the adult malignant glioma therapeutics market.

The infusion of government funding dedicated to brain cancer research is poised to significantly propel the growth trajectory of the adult malignant glioma therapeutics market moving forward. Government funding entails financial support disbursed by governmental bodies at various levels-federal, state, or local-towards initiatives, programs, projects, organizations, or individuals. The allocation of government funds for brain cancer research holds substantial promise for advancing adult malignant glioma therapeutics. This funding can significantly aid in the development of innovative treatments, tailored drug design, focusing on pyrimidine synthesis, and expediting orphan drug approvals. For example, in June 2023, the Australian Department of Health and Aged Care initiated the Australian Brain Cancer Mission, committing a fund of $136.66 million specifically aimed at supporting brain cancer research endeavors. The primary objective of this initiative is to double survival rates and enhance the overall quality of life for brain cancer patients, including those with anaplastic astrocytoma. Consequently, government funding geared towards brain cancer research stands as a pivotal driver propelling the adult malignant glioma therapeutics market.

The high expenses associated with chemotherapy stand as a significant constraint impacting the global adult malignant glioma therapeutics market. Chemotherapy involves the utilization of potent medications, particularly anti-cancer drugs, aimed at destroying rapidly dividing cells within the body. The fluctuating costs of chemotherapy, influenced by specific drugs and cancer types, often act as a deterrent for patients seeking access to treatment, potentially affecting their overall health and financial well-being. For instance, as reported by the National Cancer Institute in July 2022, the average expenses for medical care and medications during the first year following a cancer diagnosis exceeded $42,000, with certain procedures reaching costs surpassing $1 million. Consequently, the steep cost of chemotherapy is poised to negatively impact the adult malignant glioma therapeutics market.

Leading companies within the adult malignant glioma therapeutics market are actively engaged in the development of innovative products, notably small molecule targeted degraders, aimed at providing enhanced and dependable customer service. Small-molecule targeted degraders represent a class of drugs employing small molecules to induce the degradation of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, attained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 designed to treat glioblastoma (GBM). BEA-17 functions as a small-molecule targeted degrader targeting the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the pathogenesis of various cancers, including GBM. The drug works by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibiting the growth of cancer cells. This innovative approach holds promise in advancing treatment options within the adult malignant glioma therapeutics market.

In May 2021, Novocure Ltd., a Swiss-based pioneer in developing and producing innovative oncology therapies, formed a collaboration with GT Medical Technologies Inc. This partnership seeks to merge Tumor Treating Fields (TTFields) with GT Medical Technologies' GammaTile Surgically Targeted Radiation Therapy (STaRT) in the management of recurrent glioblastoma (GBM). Novocure and GT Medical Technologies aim to commence a phase 2 pilot study specifically designed to assess the safety and efficacy of neo-adjuvant TTFields, followed by resection, GammaTile Therapy, and adjuvant TTFields for treating recurrent GBM. GT Medical Technologies Inc., headquartered in the United States, specializes in providing surgically targeted radiation therapy catering to various malignant brain tumors in adult patients.

Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

North America was the largest region in the adult malignant glioma therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adult Malignant Glioma Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adult malignant glioma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adult malignant glioma therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adult malignant glioma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types
  • 2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies
  • 3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users
  • Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Allergan plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adult Malignant Glioma Therapeutics Market Characteristics

3. Adult Malignant Glioma Therapeutics Market Trends And Strategies

4. Adult Malignant Glioma Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Adult Malignant Glioma Therapeutics Market Size and Growth

  • 5.1. Global Adult Malignant Glioma Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Adult Malignant Glioma Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Adult Malignant Glioma Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Adult Malignant Glioma Therapeutics Market Segmentation

  • 6.1. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Other Types
  • 6.2. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Targeted Therapy
  • Radiotherapy
  • Other Therapies
  • 6.3. Global Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Cancer And Radiation Therapy Centers
  • Other End Users

7. Adult Malignant Glioma Therapeutics Market Regional And Country Analysis

  • 7.1. Global Adult Malignant Glioma Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Adult Malignant Glioma Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Adult Malignant Glioma Therapeutics Market

  • 8.1. Asia-Pacific Adult Malignant Glioma Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Adult Malignant Glioma Therapeutics Market

  • 9.1. China Adult Malignant Glioma Therapeutics Market Overview
  • 9.2. China Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Adult Malignant Glioma Therapeutics Market

  • 10.1. India Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Adult Malignant Glioma Therapeutics Market

  • 11.1. Japan Adult Malignant Glioma Therapeutics Market Overview
  • 11.2. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Adult Malignant Glioma Therapeutics Market

  • 12.1. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Adult Malignant Glioma Therapeutics Market

  • 13.1. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Adult Malignant Glioma Therapeutics Market

  • 14.1. South Korea Adult Malignant Glioma Therapeutics Market Overview
  • 14.2. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Adult Malignant Glioma Therapeutics Market

  • 15.1. Western Europe Adult Malignant Glioma Therapeutics Market Overview
  • 15.2. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Adult Malignant Glioma Therapeutics Market

  • 16.1. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Adult Malignant Glioma Therapeutics Market

  • 17.1. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Adult Malignant Glioma Therapeutics Market

  • 18.5. France Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Adult Malignant Glioma Therapeutics Market

  • 19.9. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Adult Malignant Glioma Therapeutics Market

  • 20.13. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Adult Malignant Glioma Therapeutics Market

  • 21.1. Eastern Europe Adult Malignant Glioma Therapeutics Market Overview
  • 21.2. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Adult Malignant Glioma Therapeutics Market

  • 22.1. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Adult Malignant Glioma Therapeutics Market

  • 23.1. North America Adult Malignant Glioma Therapeutics Market Overview
  • 23.2. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Adult Malignant Glioma Therapeutics Market

  • 24.1. USA Adult Malignant Glioma Therapeutics Market Overview
  • 24.2. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Adult Malignant Glioma Therapeutics Market

  • 25.1. Canada Adult Malignant Glioma Therapeutics Market Overview
  • 25.2. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Adult Malignant Glioma Therapeutics Market

  • 26.1. South America Adult Malignant Glioma Therapeutics Market Overview
  • 26.2. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Adult Malignant Glioma Therapeutics Market

  • 27.1. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Adult Malignant Glioma Therapeutics Market

  • 28.1. Middle East Adult Malignant Glioma Therapeutics Market Overview
  • 28.2. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Adult Malignant Glioma Therapeutics Market

  • 29.1. Africa Adult Malignant Glioma Therapeutics Market Overview
  • 29.2. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Adult Malignant Glioma Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Adult Malignant Glioma Therapeutics Market Competitive Landscape
  • 30.2. Adult Malignant Glioma Therapeutics Market Company Profiles
    • 30.2.1. Johnson & Johnson Private Limited
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bio-Rad Laboratories Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Allergan plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Adult Malignant Glioma Therapeutics Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Novartis AG
  • 31.3. Bayer AG
  • 31.4. Merck & Co Inc.
  • 31.5. GlaxoSmithKline plc
  • 31.6. Bristol-Myers Squibb Company
  • 31.7. Abbott Laboratories
  • 31.8. AstraZeneca plc
  • 31.9. Eli Lilly and Company
  • 31.10. Amgen Inc.
  • 31.11. Teva Pharmaceutical Industries Ltd.
  • 31.12. GT Medical Technologies Inc.
  • 31.13. Lupin Limited
  • 31.14. Mylan NV
  • 31.15. Sanofi SA

32. Global Adult Malignant Glioma Therapeutics Market Competitive Benchmarking

33. Global Adult Malignant Glioma Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Adult Malignant Glioma Therapeutics Market

35. Adult Malignant Glioma Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Adult Malignant Glioma Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Adult Malignant Glioma Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Adult Malignant Glioma Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer